Community-acquired pneumonia mortality: a potential link to antibiotic prescribing trends in general practice  by Price, David B et al.
Community-acquired pneumonia mortality:
a potential link to antibiotic prescribing trends
in general practice
David B. Pricea,*, David Honeybourneb, Paul Littlec, Richard T. Mayon-
Whited, Robert C. Reade, Mike Thomasa,f, Martin C. Waleg,
Patrick FitzGeraldh,i, Ad "ele R. Westonh,j,k, Christopher C. Winchesterl,m
aDepartment of General Practice and Primary Care, Foresterhill Health Centre, University of Aberdeen,
Westburn Road, Aberdeen AB25 2AY, UK
bDepartment of Respiratory Medicine, Birmingham Heartlands Hospital, Bordesley Green East,
Birmingham B9 5SS, UK
cCommunity Clinical Sciences, Primary Medical Care Group, Faculty of Health, Medicine and Biological
Sciences, Aldermoor Health Centre, Southampton University, Southampton SO16 5ST, UK
dInstitute of Health Sciences, Old Road, Oxford OX3 7LF, UK
eDivision of Molecular and Genetic Medicine, F Floor, University of Sheffield Medical School,
Beech Hill Road, Sheffield S10 2RX, UK
fMinchinhampton Surgery, Minchinhampton, Stroud, Gloucestershire GL6 9JF, UK
gPHLS Antimicrobial Susceptibility Surveillance Unit, Queen’s Medical Centre, Nottingham NG7 2UH, UK
hM-TAG Pty Ltd, Level 3, 845 Pacific Hwy, Chatswood NSW 2067, Australia
iCentre for Clinical Epidemiology and Biostatistics, University of Newcastle, NSW, Australia
jFaculty of Health Sciences, University of Sydney, NSW, Australia
kHealth Technology Analysts Pty Ltd, Level 1, 21A Elliott St. P.O. Box 133, Balmain NSW 2041, Australia
lHealthworld Communications Group, The Mitfords, Basingstoke Road, Three Mile Cross, Reading,
Berkshire RG7 1AT, UK
mOxford Pharma Genesis Ltd. 1, Tubney Warren Barns Tubney, Oxford OX13 5QJ, UK
Received 24 April 2003; accepted 20 August 2003
Summary Background: Community prescribing of antibiotics has decreased substan-
tially in the UK in recent years. We examine the association between pneumonia
mortality and recent changes in community-based antibiotic prescribing for lower
respiratory tract infections (LRTI).
Methods: Retrospective analysis of aggregated data for pneumonia mortality,
influenza incidence, and antibiotic prescribing for LRTI in England and Wales during
12-week winter periods between 1993/94 and 1999/2000.
Results: Winter antibiotic prescribing for LRTI showed a 30.0% decline since 1995/
96. Over the same period, there was a 50.6% increase in winter excess pneumonia
mortality adjusted for influenza incidence. Negative binomial regression analysis
showed that the incidence of influenza alone had a significant association with winter
pneumonia mortality (Po0:001). The analysis also showed the reduction in antibiotic
prescribing had a small but significant association with mortality (Po0:001), when
simultaneously modelling for influenza incidence.
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Conclusions: Our findings suggest an association between recent reductions in
antibiotic prescribing for LRTI in general practice and an increase in pneumonia
mortality in England and Wales. This retrospective study of aggregate data represents
the first attempt to assess the effect of limiting antibiotic prescribing on patient
outcomes, and highlights the need to identify which patients benefit from antibiotic
treatment for LRTI.
& 2003 Elsevier Ltd. All rights reserved.
Introduction
Pneumonia is a major cause of morbidity and
mortality worldwide. In the UK as a whole,
pneumonia is responsible for over 10% of all deaths
(66,581 deaths in 1999), the majority of which
occur in the elderly.1 In England, it accounted for
79,124 hospital admissions in 1999/2000, resulting
in almost a million patient-days in hospital.1 In the
USA, 267 people per 100,000 population were
hospitalised with community-acquired pneumonia
(CAP) in 1991, with an overall case fatality rate of
8.8%.2 In 1999, pneumonia and influenza were the
seventh largest cause of mortality in the USA,
accounting for a total of 63,730 deaths.3
Pneumonia morbidity and mortality show con-
siderable seasonal variation. Pneumonia mortality
rates are higher in the winter than the summer, and
hospital admissions for pneumonia occur mainly
during the winter months,4,5 putting a considerable
burden on healthcare services through this period.6
The increased pneumonia morbidity and mortality
seen during winter months can be expressed as a
‘winter excess’: the increase above the baseline
levels of non-winter months. This excess is strongly
influenced by the seasonal variations in influenza
infection,4,5,7 because viral respiratory tract infec-
tion predisposes individuals to opportunistic bac-
terial infection.8 This link with bacterial infection
suggests that winter excess pneumonia morbidity
and mortality may be susceptible to changes in
antibiotic prescribing practices.
In recent years, there have been worldwide
efforts to reduce inappropriate antibiotic prescrib-
ing in response to mounting concerns about the
emergence of antimicrobial resistance. In the UK,
antibiotic prescribing has substantially decreased,
particularly among the broad-spectrum penicillins
and macrolides commonly prescribed for LRTI.9,10
Reductions in antibiotic prescriptions have also
taken place in European countries,11 while in the
USA, large reductions have occurred among chil-
dren,12,13 although data are not yet available for
the US population as a whole.
To the best of our knowledge, no formal review
of the impact of this reduction in antibiotic
prescriptions on morbidity and mortality has been
planned or conducted to date. We therefore set out
to investigate whether there was any association
between recent changes in antibiotic prescribing
for LRTI and winter pneumonia mortality in England
and Wales.
Methods
Data sources
Pneumonia mortality
Pneumonia mortality data were obtained from the
Office of National Statistics, using the 9th revision
of the International Classification of Diseases (ICD-9)
codes 480–486. These data exclude deaths from
pneumonia as a consequence of underlying dis-
ease.14 Data prior to 1993/94 were omitted
because of a change in ICD-9 mortality coding at
the start of 1993.14 Similarly, data collection was
not extended beyond 2000 because of a coding
change to ICD-10 in January 2001 that may have
confounded the analyses.15 All analyses were
therefore performed using data for England and
Wales from winter 1993/94 to winter 1999/2000.
We present winter pneumonia mortality data as a
‘winter excess’ value to exclude events that occur
consistently throughout the year.16 A constant
number of deaths was subtracted from winter
values across all years to remove those not related
to influenza, producing the winter excess value.
The arbitrary constant used was 85% of the lowest
summer pneumonia mortality valueFequal to 7600
deaths for the 12-week study period. Using a
constant enabled better quantification of events
secondary to winter infectious agents without the
introduction of additional bias. Annual totals for
pneumonia mortality were also obtained for com-
parative purposes.
Influenza incidence
The incidence of influenza in the community was
estimated from data on ‘influenza and influenza-
like illness’ visits to the Royal College of General
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Practitioners sentinel group of 70 general prac-
tices, and extrapolated to the population of
England and Wales. The sentinel group is represen-
tative of general practices across England and
Wales,17 and the clinical diagnoses it records have
been shown to correlate strongly with laboratory-
confirmed influenza infections.18 Patient demo-
graphic data within the group are comparable with
census data, and with general practices as a
whole.19 Collection of 12-week influenza data
started 2 weeks prior to the 12-week collection
period for mortality and antibiotic prescribing
data. This allows time for secondary infection and
progression to death to occur, and is standard
practice when evaluating influenza-related out-
comes.20
Antibiotic prescribing
We obtained winter antibiotic prescribing data
from the IMS Health UK MediPluss database, which
has also been used in recent antibiotic resistance
studies.21,22 This database records deidentified
weekly prescribing and patient morbidity data from
a sentinel group of 462 general practices, which are
monitored to ensure that they are representative
of general practice as a whole.23 Data regarding
antibiotic prescriptions for LRTI [READ codes J13.0
(Pneumonia due to Streptococcus pneumoniae),
J15.7 (Pneumonia due to Mycoplasma pneumo-
niae), J15.9 (Bacterial pneumonia, unspecified),
J18.0 (Bronchopneumonia, unspecified), J18.2
(Hypostatic pneumonia, unspecified), J18.9 (Pneu-
monia, unspecified), J20.9 (Acute bronchitis, un-
specified), J21.9 (Acute bronchiolitis, unspecified),
J22.0 (Unspecified acute lower respiratory infec-
tion), J44.1 (Chronic obstructive pulmonary disease
with acute exacerbations, unspecified), J44.8
(Other specified chronic obstructive pulmonary
disease), J44.9 (Chronic obstructive pulmonary
disease, unspecified), J40.0 (Bronchitis, not speci-
fied as acute or chronic), J41.0 (Simple chronic
bronchitis), J41.1 (Mucopurulent chronic bronchi-
tis), J42.0 (Unspecified chronic bronchitis) and
J42.9 (Emphysema, unspecified)] were then extra-
polated to the population of England and Wales.
Annual totals for antibiotic prescribing for LRTI
were also obtained for comparative purposes.
These estimates were validated using Prescribing
Analysis and Cost (PACT) data from the UK National
Health Service (NHS) Prescription Pricing Authority
(PPA). PPA data are provided by antibiotic type, not
by indication or diagnosis, and are available only
quarterly and for England alone. We therefore
collected data for one quarter (January to March)
for each winter and assumed that a constant
proportion (20%) of broad-spectrum penicillin and
macrolide prescribing was for LRTI.
Population data
Annual population data for England and Wales were
obtained from the Office of National Statistics.
Winter analysis period
The time period used for the analyses was derived
from the findings of a Lung and Asthma Institute
report commissioned by the UK Department of
Health, which examined the seasonality of pneu-
monia mortality from 1991 to 1995.24 The period
selected was based on the criterion that mortality
values be above the midpoint between the summer
trough and the winter peak in pneumonia mortality.
As a result, we chose a 12-week period starting at
the beginning of December (week 48).
Statistical analyses
Negative binomial regression analysis was used to
examine the change in winter mortality over time.
This is a Poisson regression analysis with additional
correction applied for any extra-Poisson dispersion.
It was selected because it best reflected the shape
of the assumed underlying distribution of pneumo-
nia mortality. A Poisson distribution is a common
assumption with count data leading to rate vari-
ables such as pneumonia mortality. The additional
correction was applied to take into account a
potential lack of independence of deaths caused by
epidemic-like conditions often associated with
influenza outbreaks.
We used a sequential model to assess the
incremental contribution of influenza and antibio-
tic prescriptions to pneumonia mortality. As the
incidence of influenza is known to be closely
correlated with winter pneumonia mortality, it
was included as the primary predictor. The rate of
antibiotic prescribing for LRTI was included as the
secondary predictor. The resultant coefficients
were calculated as log rate ratios and converted
to rate ratios.
Sensitivity analyses were performed in order to
investigate the robustness of the results in the face
of alternative data sources or data extraction
methods. The first sensitivity analysis included an
additional temporal variable in the regression
analysis to detect any unspecified factors that
might be changing progressively across the years.
Two further analyses were conducted in which the
time period analysed was extended equilaterally to
16 and 20 weeks.
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In addition, two alternative regression models
were used to gauge the robustness of the data
analysis. Analyses were performed using a Poisson
regression model with robust standard errors (a less
conservative approach than the negative binomial
regression) and a least-squares regression (a more
conservative approach as it assumes a normal
distribution, which is not likely in the case of death
rates).
All data included in the regression analysis were
expressed as rates per 1000 of the population of
England and Wales for each year. Statistical
analyses were performed using Stata version 6
software.
Results
Trends in winter pneumonia mortality
Data from the Office of National Statistics showed
an almost two-fold variation in pneumonia mortal-
ity during the 12-week winter period across the 7
years of investigation (Fig. 1). The incidence of
influenza for the corresponding period showed a
high degree of correlation with pneumonia mortal-
ity (r ¼ 0:91), with the mortality curve closely
resembling that of community influenza (Fig. 1). In
contrast, when pneumonia mortality and influenza
data were examined over a 12-week summer
period, pneumonia deaths appeared quite indepen-
dent of influenza levels (Fig. 1).
Winter pneumonia mortality for each year was
standardised to average influenza levels purely to
allow year-by-year trends to be visualised. This
revealed that winter excess pneumonia mortality
for the 12-week periods increased by 50.6%
between 1995/96 (shortly before the fall in anti-
biotic prescribing) and 1999/2000, from 20.4
deaths/100,000 to 30.7 deaths/100,000 (Fig. 2).
IMS data for the same winter periods showed a
30.0% decline in community antibiotic prescriptions
for LRTI, from 42.3 prescriptions/1000 in 1995/96
to 29.6 prescriptions/1000 in 1999/2000 (Fig. 2).
The IMS antibiotic prescribing data were vali-
dated with 13-week antibiotic data (January to
March) obtained from the PPA. The two data sets
showed identical trends in winter community
antibiotic prescriptions from winter 1993/94 to
1999/2000. A strong correlation was observed
between the two data sets (R2 ¼ 0:85).
Regression analysis of winter pneumonia
mortality data
Negative binomial regression analysis of the raw 12-
week winter data showed that the incidence of
community influenza alone was significantly asso-
ciated with excess winter pneumonia mortality
(Po0:001; Table 1). When the model included both
influenza and antibiotic prescribing as variables,
the reduction in antibiotic prescribing for LRTI was
significantly associated with mortality (Po0:001;
Table 1).
The results of the negative binomial regression
analysis indicated that antibiotic prescribing for
LRTI had a smaller effect on winter pneumonia
mortality than influenza incidence. Nevertheless,
ARTICLE IN PRESS
Figure 1 Variations in influenza incidence and pneumo-
nia mortality during the 12-week winter analysis period
between 1993/94 and 1999/2000.
Figure 2 Trends in antibiotic prescribing for lower
respiratory tract infection and excess winter pneumonia
mortality. To take into account the large effect of
influenza on winter pneumonia mortality, the data were
standardised to the average influenza incidence over the
analysis period (1993/94–1999/2000) using the actual
data for each year (i.e. divide by the actual influenza
incidence then multiply by the average influenza in-
cidence of 9.95 visits/1000 population).
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when a typical reduction in winter antibiotic
prescriptions for LRTI of 10 prescriptions/1000
(Fig. 2) is applied to a constant influenza consulta-
tion rate of 9.95 visits/1000 (the mean for the
study period), the model predicts an increase in
winter pneumonia mortality of 3195 across the
winter period (assuming a population of 50 million
for England and Wales), independent of changes in
other determinants. This equates to approximately
one extra death from CAP for every 160 fewer
winter antibiotic prescriptions for LRTI in general
practice.
Sensitivity analyses confirmed that our conclu-
sions are robust. The temporal variable, included to
detect any unspecified factors changing progres-
sively from year to year (for example, the effects of
an ageing population), had no significant effect on
pneumonia mortality (P ¼ 0:155). Furthermore, the
inclusion of this variable in the model did not alter
the effect of influenza or antibiotic prescribing
upon pneumonia mortality (both remained
Po0:001), although the magnitude of the antibiotic
effect (2609 additional deaths) is reduced slightly.
Similarly, extending the data period equilaterally
from 12 weeks to 16 weeks and 20 weeks had little
effect on the results (Table 2).
Data analyses using alternative regression models
also support the robustness of our findings. Both the
influenza effect and the antibiotic prescribing
effect were significant when the data were
analysed by Poisson regression with robust standard
errors (influenza effect, Po0:001; antibiotic pre-
scribing effect, Po0:001) and by normal distribu-
tion least-squares regression (influenza effect,
P ¼ 0:002; antibiotic prescribing effect, P ¼ 0:026;
Table 3). The comparatively small R2 values
observed with the negative binomial regression
compared with these two models reflect the large
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Table 1 Incremental results of negative binomial regression models (Stata v6).
Effect Estimated rate ration 95% CI P value R2w
Influenza visits/1000z 1.123 1.077, 1.171 o0.001 0.082
Influenza visits/1000z 1.136 1.119, 1.153 o0.001 0.187
Antibiotic prescriptions/1000z 0.974 0.966, 0.981 o0.001
nCalculated from the estimated log-rate ratios.
wPseudo-R2 reported for negative binomial regression models.
zVisits to the general practitioner for influenza or influenza-like illness.
zThe antibiotic effect in the complete model, 0.974, is the ratio of the rate of change of mortality to the rate of change of
antibiotic prescribing, i.e. deaths/1000 population for 1 script/1000 change in prescribing. Therefore a ratio of 1.00 would
indicate no effect. The ratio appearing in one row is adjusted for the variables present in the other rows of the model, in this
case for the effects of background influenza rate and year effect. The ratio shown here is below 1.00, indicating an increase in
the mortality for a decrease in the prescribing rate. Note that changes in the rate of prescribing affect the rate of mortality in a
multiplicative, i.e. non-linear, way.
Table 2 Sensitivity analyses using negative binomial regression models.
Alternative analysis Effect Estimated
rate ration
95% CI P value R2w
Extending winter period to
16 weeks (starting in week 46)
Influenza visits/1000z 1.096 1.064, 1.130 o0.001 0.096
Antibiotic prescriptions/1000 0.978 0.968, 0.989 o0.001
Extending winter period to
20 weeks (starting in week 44)
Influenza visits/1000z 1.078 1.044, 1.113 o0.001 0.079
Antibiotic prescriptions/1000 0.978 0.966, 0.988 o0.001
Inclusion of temporal variable Influenza visits/1000z 1.131 1.115, 1.148 o0.001 0.200
Antibiotic prescriptions/1000 0.978 0.969, 0.987 o0.001
Temporal effect 1.019 0.993, 1.046 0.155
nCalculated from the estimated log-rate ratios.
wPseudo-R2 reported for negative binomial regression models.
zVisits to the general practitioner for influenza or influenza-like illness.
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variance applied in the conservative negative
binomial regression method.
Discussion
The key finding to emerge from our study is the
significant association between the extent of
antibiotic prescribing for LRTI and winter pneumo-
nia mortality. Our results suggest that, when
simultaneously modelled with influenza incidence,
the increase in excess winter pneumonia mortality
seen in recent years is associated with a reduction
in antibiotic prescriptions for LRTI. However, care
must be taken when interpreting the results of this
study, given that it involved aggregate data from
across England and Wales, and therefore cannot be
used to determine cause and effect, and that the
findings are based on the limited number of data
points available between recent changes in mor-
tality coding.
Initial investigations showed that, if the mortal-
ity data were standardised to the average influenza
incidence, there was a 50.6% increase in excess
winter pneumonia mortality between 1995/96 and
1999/2000. Our analysis showed that winter anti-
biotic prescribing for LRTI declined by 30.0% over
the same period, a finding that appears to be
confirmed by data from the PPA.
Regression analysis revealed that the incidence
of community influenza had a significant effect on
the variations in excess winter pneumonia mortal-
ity in England and Wales from 1993 to 2000. The
exact magnitude of summer pneumonia mortality
used in calculating this winter excess does not
affect this statistical relationship, only the percen-
tage change in mortality over time. The association
between pneumonia and influenza is already well
established, both statistically and aetiologi-
cally.5,8,25 It is this link with pneumonia, rather
than the relatively small disease burden of influ-
enza itself, that provides the rationale for influenza
vaccination of the elderly, the immunocompro-
mised and those with underlying lung and cardio-
vascular disease.26
The regression analysis also showed that the
extent of antibiotic prescribing for LRTI had a small
but significant association with pneumonia mortal-
ity. The concurrent significant effects of influenza
and antibiotic prescribing occurred over and above
any linear changes over the same period (for
example, those progressive changes that might
result from an ageing population, the spread of
resistance, or changing patterns of healthcare),
which were accounted for by a separate temporal
variable. Furthermore, the results were robust in
the face of different methods of data extraction
and analysis. Nevertheless, it is not possible to
exclude some possible confounding factors, such as
changing patterns of diagnosis over the period
studied.
Annual data from the PPA show that total
antibiotic prescribing in England has fallen by just
under one quarter, from a peak level of 44.5 million
prescriptions in 1995/96 to 34.2 million prescrip-
tions in 1999/2000.9 A recent study showed that
this decline occurred across all age groups.10 Our
study identified a reduction in winter antibiotic
prescribing for LRTI of almost one-third. Similar
trends were seen in a sample of general practices in
the West Midlands region of England between 1993
and 1997, which showed a sharper decline in
antibiotic prescribing for LRTI than in overall
antibiotic prescribing.27
The substantial decrease in antibiotic prescribing
for LRTI appears surprising, given that the focus of
recent advice from the UK government has been to
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Table 3 Results using alternative regression models.
Alternative regression
models
Effect Estimated
effectsn
95% CI P value R2w
Poisson regression with
robust standard errors
Influenza visits/1000z 1.139 1.120, 1.158 o0.001 0.959
Antibiotic prescriptions/1000 0.974 0.964, 0.984 o0.001
Least-squares linear
regression
Influenza visits/1000z 0.0267 0.0167, 0.0367 0.002 0.903
Antibiotic prescriptions/1000 –0.0062 –0.0112, –0.0012 0.026
nRate ratio in the case of Poisson regression, slope coefficient in the case of linear regression.
wPseudo-R2 reported for negative binomial regression models.
zVisits to the general practitioner for influenza or influenza-like illness.
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reduce antibiotic prescribing for upper respiratory
and urinary tract infection rather than LRTI.28 A
systematic review of the small number of relevant
randomised controlled trials concludes that anti-
biotics have a modest benefit in treating symptoms
of LRTI,29 suggesting that delays in antibiotic
prescribing are unlikely to cause harm in most LRTI
patients. However, for the small minority who
develop pneumonia, delayed or insufficient
antibiotic treatment is an important prognostic
factor.30–32
Although comprehensive guidelines on the diag-
nosis and treatment of pneumonia have recently
been published in the UK,33 it is difficult to
diagnose pneumonia in general practice.33 Given
this, it is important to be able to identify which
patients with LRTI are potentially at risk from
pneumonia if not treated promptly. There is,
therefore, an urgent need for retrospective case
control studies and large prospective randomised
clinical studies to identify those patients with LRTI
who will selectively benefit from antibiotics and
allow the development of appropriate treatment
guidelines for LRTI.
A number of other questions raised by the
present study also need to be addressed, in
particular whether or not the association is causal.
Further research is needed to determine whether
the decline in prescribing and increase in mortality
occur in particular groups of patients (e.g. the
elderly) and to identify whether the effect is
limited to certain groups of prescribers. Factors
such as changing patterns of disease (e.g. anti-
microbial resistance, influenza virulence, pneumo-
coccal infection or respiratory syncytial virus
infection), of healthcare (e.g. changing thresholds
for admission to hospital), and of diagnosis and
death certification (e.g. diagnosis of pneumonia
versus acute exacerbation of chronic obstructive
pulmonary disease) may have had an effect and
need to be investigated. In particular, influenza and
pneumococcal vaccination campaigns in the UK in
recent years34,35 would be expected to reduce
winter pneumonia mortality over the study period.
In a survey of general practices in Scotland,
influenza vaccination rates increased by more than
50% between 1993 and 1999(from 72.2 doses per
1000 population to 111.0 dose/1000), while pneu-
mococcal vaccination increased 26-fold (from 1.9
doses/1000 to 50.1 doses/1000) over the same
period.35
The findings of this study have implications for
healthcare practice beyond England and Wales. The
need to reduce inappropriate antibiotic prescribing
to combat microbial resistance is recognised world-
wide, and reductions in antibiotic prescribing have
been seen in other European countries11 and among
children in the US.12,13 Our findings suggest a need
for studies examining the changing patterns of
antibiotic prescribing and their effects on patient
outcomes in other countries. Such studies may
provide a useful comparison with the changes
observed in England and Wales, and could help to
improve antibiotic prescribing practices worldwide.
In conclusion, our findings suggest that there may
be an association between changes in antibiotic
prescribing for lower respiratory tract infection in
general practice and changes in pneumonia mor-
tality in England and Wales, although it is important
to note that the association is not necessarily
causal, and could be due to an as yet unidentified
confounding factor. Further research into the
effects of controlling antibiotic use on the out-
comes of respiratory infections is therefore war-
ranted, especially in patients at high risk of
complications.
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